Johnson & Johnson Medical Devices Companies Announces New Neurovascular Business

Johnson & Johnson Medical Devices Companies recently introduced CERENOVUS, its new neurovascular business, at the Society of NeuroInterventional Surgery (SNIS) 14th Annual Meeting in Colorado. CERENOVUS, a name derived from the Latin words for “new” and “brain,” will focus on delivering innovative therapies for hemorrhagic and ischemic stroke patients.  
 
“Our neurovascular business is evolving and CERENOVUS reflects our bold new vision, positioning and priorities,” said Shlomi Nachman, company group chairman of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “Inspired by how quickly a stroke can affect a person’s mind and our commitment to reducing the devastating impact, CERENOVUS aims to help physicians give stroke patients a new lease on life.”
 
The Johnson & Johnson Medical Devices Companies are committed to neurovascular care, having expanded CERENOVUS’s product portfolio in the last year with targeted investments. The recent acquisitions of Pulsar Vascular Inc., with a specialty in the endovascular treatment of wide-neck bifurcation aneurysms, and Neuravi Limited, offering extensive expertise and knowledge in acute ischemic stroke with its EmboTrap Revascularization Platform, greatly extend CERENOVUS’s abilities to address unmet clinical needs in these areas.  
 
Globally, stroke is the second leading cause of death after the age of 60.¹ The American Heart Association estimates someone dies of a stroke every four minutes.² In the United States alone, the economic burden of stroke is estimated at $33 billion annually, which includes the cost of health care services, medications, and lost productivity.³
 
CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, is focused on neurovascular care. Part of DePuy Synthes Products Inc., CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke.
 
The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.
 
References
1. World Heart Federation http://www.world-heart-federation.org/cardiovascular-health/stroke/
2. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association http://circ.ahajournals.org/content/135/10/e146#sec-2
3. Centers for Disease Control https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/docs/fs_stroke.pdf